<?xml version="1.0" encoding="UTF-8"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-10-19T02:18:25Z</responseDate><request verb="GetRecord" identifier="oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/16792" metadataPrefix="oai_dc">https://ebyu-rdlopen.rawdatalibrary.net/oai/request</request><GetRecord><record><header><identifier>oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/16792</identifier><datestamp>2026-10-18T20:38:54Z</datestamp><setSpec>openaire</setSpec><setSpec>driver</setSpec><setSpec>com_ebyu_10000</setSpec><setSpec>col_ebyu_10001</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><dc:title>Effect of Taxifolin on Lung Injury Induced by Staphylococcus aureus in Albino Wistar-Type Rats: A Biochemical and Histopathological Evaluation</dc:title><dc:creator>Dabanlioglu, Bulent</dc:creator><dc:creator>Suleyman, Bahadir</dc:creator><dc:creator>Mammadov, Renad</dc:creator><dc:creator>Yavuzer, Bulent</dc:creator><dc:creator>Altuner, Durdu</dc:creator><dc:creator>Akkas, Onder</dc:creator><dc:creator>Mokhtare, Behzad</dc:creator><dc:creator>Coban, Taha Abdulkadir</dc:creator><dc:creator>Suleyman, Halis</dc:creator><dc:subject>Lung injury</dc:subject><dc:subject>oxidative and inflammatory injury</dc:subject><dc:subject>rats</dc:subject><dc:subject>Staphylococcus aureus</dc:subject><dc:subject>taxifolin</dc:subject><dc:subject>NF-KAPPA-B</dc:subject><dc:subject>ISCHEMIA-REPERFUSION INJURY</dc:subject><dc:subject>OXIDATIVE STRESS</dc:subject><dc:subject>IN-VITRO</dc:subject><dc:subject>INFLAMMATION</dc:subject><dc:subject>OSTEOCLASTOGENESIS</dc:subject><dc:subject>PATHOGENESIS</dc:subject><dc:subject>PNEUMONIA</dc:subject><dc:subject>MECHANISM</dc:subject><dc:subject>Pharmacology &amp; Pharmacy</dc:subject><dc:description>Background and Objective: Staphylococcus aureus is considered the main cause of pneumonia. Pneumonia is the most common cause of acute lung injury. Taxifolin is a flavonol with antioxidant, anti-inflammatory, antimicrobial, antiviral, antifungal, anti-hyperglycemic, anti-hyperlipidemic, anti-psoriatic and pulmono-protective activities. The present study aimed to biochemically and histopathologically investigate the protective effect of taxifolin against possible acute lung oxidative and inflammatory damage caused by Staphylococcus aureus ( S. aureus) infection in rats. Materials and Methods: The rats were divided into three groups 6 rats each, healthy control (HG), S. aureus inoculated (SaG) and S. aureus inoculated+taxifolin treated (SaT). Animals were euthanized. Malondialdehyde (MDA) total glutathione (tGSH), Nuclear Factor kappa B (NF-kappa B), Tumor Necrosis Factor-alpha (TNF-alpha) and Interleukin One Beta (IL-1 beta) levels were measured in the excised lung tissues and also examined histopathologically. Results: S. aureus inoculation significantly increased MDA, NF-kappa B, TNF-alpha and IL-1 beta levels and decreased tGSH levels in lung tissue. Treatment with taxifolin significantly suppressed the increase in MDA, NF-kappa B, TNF-alpha and IL-1 beta levels and the decrease in tGSH levels. Histopathologically, S. aureus inoculation led to severe mononuclear cell infiltration in interstitial areas, lymphoid hyperplasia in bronchial-associated lymphoid tissue and desquamation in bronchial epithelium. Treatment with taxifolin attenuated these histopathological findings. Conclusion: Current experimental results suggested that taxifolin may be beneficial in the treatment of oxidative and inflammatory lung injury associated with S. aureus infection.</dc:description><dc:publisher>ASIAN NETWORK SCIENTIFIC INFORMATION-ANSINET</dc:publisher><dc:date>2023</dc:date><dc:type>Article</dc:type><dc:identifier>https://rdlopen.rawdatalibrary.net/r/ebyu/16792</dc:identifier><dc:identifier>https://doi.org/10.3923/ijp.2023.623.631</dc:identifier><dc:identifier>1811-7775</dc:identifier><dc:language>en</dc:language><dc:relation>INTERNATIONAL JOURNAL OF PHARMACOLOGY</dc:relation><dc:rights>info:eu-repo/semantics/openAccess</dc:rights><dc:type>info:eu-repo/semantics/article</dc:type><dc:identifier>https://ebyu-rdlopen.rawdatalibrary.net/tr/items/ebyu/16792</dc:identifier></oai_dc:dc></metadata></record></GetRecord></OAI-PMH>